In Vitro Probiotic Modulation of the Intestinal Microbiota and 2′Fucosyllactose Consumption in Fecal Cultures from Infants at Two Months of Age

Nogacka, Alicja; Arboleya, Silvia; Nikpoor, Naghmeh; Auger, Jérémie; Salazar, Nuria; Cuesta, Isabel; Álvarez-Buylla, Jorge R.; Mantecón, Laura; Solı́s, Gonzalo; Gueimonde, Miguel; Tompkins, Thomas A.

doi:10.3390/microorganisms10020318

Cited by 9 publications

(11 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increase in this metabolite in FF newborns is driven by the catabolic pathways of amino acids, such as isoleucine, which is found in high-protein infant formulae. Moreover, recent studies of fecal cultures of healthy 2-month-old neonates revealed the interrelation of succinate compounds with the establishment of commensal Enterobacteriaceae communities in the FF infant gut [ 65 ]. Apart from the feeding mode, the concentrations of methyl-succinate has been shown to significantly depend on the age of the infant [ 64 ].…”

Section: Discussionmentioning

confidence: 99%

Urine Metabolomic Profile of Breast- versus Formula-Fed Neonates Using a Synbiotic-Enriched Formula

Falaina

Fotakis

Boutsikou

et al. 2022

IJMS

View full text Add to dashboard Cite

The aim of this study was to compare the urine metabolic fingerprint of healthy neonates exclusively breastfed with that of neonates fed with a synbiotic-enriched formula (Rontamil® Complete 1) at four time points (the 3rd and 15th days of life and the 2nd and 3rd months). The determination of urine metabolic fingerprint was performed using NMR metabolomics. Multivariate data analyses were performed with SIMCA-P 15.0 software and R language. Non-distinct profiles for both groups (breastfeeding and synbiotic formula) for the two first time points (3rd and 15th days of life) were detected, whereas after the 2nd month of life, a discrimination trend was observed between the two groups, which was further confirmed at the 3rd month of life. A clear discrimination of the synbiotic formula samples was evident when comparing the metabolites taken in the first days of life (3rd day) with those taken in the 2nd and 3rd months of life. In both cases, OPLS-DA models explained more than 75% of the metabolic variance. Non-distinct metabolomic profiles were obtained between breastfed and synbiotic-formula-fed neonates up to the 15th day of life. Discrimination trends were observed only after the 2nd month of the study, which could be attributed to breastfeeding variations and the consequent dynamic profile of urine metabolites compared to the stable ingredients of the synbiotic formula.

show abstract

Section: Discussionmentioning

confidence: 99%

Urine Metabolomic Profile of Breast- versus Formula-Fed Neonates Using a Synbiotic-Enriched Formula

Falaina

Fotakis

Boutsikou

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Supplementation with HMOs may therefore potentially increase bifidobacteria and bring microbiota composition closer to that of breastfed infants. In RCT, the microbiota composition in a 2’-FL formula (1 g/L) group was only just significantly different at 2 months and just not at 3 months of age, bringing the microbiota composition somehow closer to that of breastfed infants 159 .…”

Section: Hmos and Anthropometrymentioning

confidence: 91%

“… Infants receiving HMO containing formula had significantly fewer parental reports of parent-reported morbidities related to lower respiratory tract infections as well as antipyretic and antibiotic. Alliet et al 159 2022 2’FL + L. Reuteri DSM 17,938 Belgium, Italy 2017–2019 Healthy, term (37–42 weeks gestation) infants aged≤14 days at enrollment with a birth weight between 2500 and 4500 g Standard bovine milk-based whey predominant formula with an energy density of 670 kcal/L containing 75 g/L lactose, 34 g/L fat, 14 g/L protein (60:40 whey: casein ratio), and L. reuteri DSM 17,938 + 1 g/L 2’FL which i Standard bovine milk-based whey predominant formula with an energy density of 670 kcal/L containing 75 g/L lactose, 34 g/L fat, 14 g/L protein (60:40 whey:casein ratio), and L. reuteri DSM 17,938 Breastfed infants 180 days Weight gain in HMO formula was non-inferior to a non-HMO supplemented formula. Anthropometric Z-scores, parent-reported stooling characteristics, gastrointestinal symptoms and associated behaviors, and AEs were comparable between formula groups.…”

Section: Hmos and Anthropometrymentioning

confidence: 99%

Functional effects of human milk oligosaccharides (HMOs)

et al. 2023

View full text Add to dashboard Cite

Human milk oligosaccharides (HMOs) are the third most important solid component in human milk and act in tandem with other bioactive components. Individual HMO levels and distribution vary greatly between mothers by multiple variables, such as secretor status, race, geographic region, environmental conditions, season, maternal diet, and weight, gestational age and mode of delivery. HMOs improve the gastrointestinal barrier and also promote a bifidobacterium-rich gut microbiome, which protects against infection, strengthens the epithelial barrier, and creates immunomodulatory metabolites. HMOs fulfil a variety of physiologic functions including potential support to the immune system, brain development, and cognitive function. Supplementing infant formula with HMOs is safe and promotes a healthy development of the infant revealing benefits for microbiota composition and infection prevention. Because of limited data comparing the effect of non-human oligosaccharides to HMOs, it is not known if HMOs offer an additional clinical benefit over non-human oligosaccharides. Better knowledge of the factors influencing HMO composition and their functions will help to understand their short- and long-term benefits.

show abstract

“…Batch cultivation and the CoMiniGut model (University of Copenhagen, Copenhagen, Denmark) have been used to evaluate the effects of 3-FL on the infant microbiota [ 30 , 31 ]. The composition of the infant microbiota varies widely between infants who donate the faecal inoculum, introducing variability in infant simulations and affecting the efficiency of HMO utilisation [ 25 , 26 , 27 , 28 , 31 , 32 ].…”

Section: Introductionmentioning

confidence: 99%

The Effect of Human Milk Oligosaccharides and Bifidobacterium longum subspecies infantis Bi-26 on Simulated Infant Gut Microbiome and Metabolites

Salli¹,

Hirvonen²,

Anglenius³

et al. 2023

Microorganisms

View full text Add to dashboard Cite

Human milk oligosaccharides (HMOs) shape the developing infant gut microbiota. In this study, a semi-continuous colon simulator was used to evaluate the effect of 2 HMOs—2′-fucosyllactose (2′-FL) and 3-fucosyllactose (3-FL)—on the composition of infant faecal microbiota and microbial metabolites. The simulations were performed with and without a probiotic Bifidobacterium longum subspecies infantis Bi-26 (Bi-26) and compared with a control that lacked an additional carbon source. The treatments with HMOs decreased α-diversity and increased Bifidobacterium species versus the control, but the Bifidobacterium species differed between simulations. The levels of acetic acid and the sum of all short-chain fatty acids (SCFAs) trended toward an increase with 2′-FL, as did lactic acid with 2′-FL and 3-FL, compared with control. A clear correlation was seen between the consumption of HMOs and the increase in SCFAs (−0.72) and SCFAs + lactic acid (−0.77), whereas the correlation between HMO consumption and higher total bifidobacterial numbers was moderate (−0.46). Bi-26 decreased propionic acid levels with 2′-FL. In conclusion, whereas infant faecal microbiota varied between infant donors, the addition of 2′-FL and 3-FL, alone or in combination, increased the relative abundance and numbers Bifidobacterium species in the semi-continuous colon simulation model, correlating with the production of microbial metabolites. These findings may suggest that HMOs and probiotics benefit the developing infant gut microbiota.

show abstract

In Vitro Probiotic Modulation of the Intestinal Microbiota and 2′Fucosyllactose Consumption in Fecal Cultures from Infants at Two Months of Age

Cited by 9 publications

References 49 publications

Urine Metabolomic Profile of Breast- versus Formula-Fed Neonates Using a Synbiotic-Enriched Formula

Urine Metabolomic Profile of Breast- versus Formula-Fed Neonates Using a Synbiotic-Enriched Formula

Functional effects of human milk oligosaccharides (HMOs)

The Effect of Human Milk Oligosaccharides and Bifidobacterium longum subspecies infantis Bi-26 on Simulated Infant Gut Microbiome and Metabolites

Contact Info

Product

Resources

About